Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

Status
Active
Cancer Type
Breast Cancer
Cervical Cancer
Colon/Rectal Cancer
Eye Cancer
Head and Neck Cancer
Kidney Cancer
Lung Cancer
Melanoma
Pancreatic Cancer
Prostate Cancer
Skin Cancer (Non-Melanoma)
Stomach/ Gastric Cancer
Unknown Primary
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT03849469
Protocol IDs
XmAb22841-01 (primary)
NCI-2019-02498
DUET-4
Study Sponsor
Xencor, Inc.

Summary

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.